AMETEK Announces Fourth Quarter 2020 Earnings Call and Webcasted Investor Conference Call Information

– Earnings to be released before market opens on Thursday, February 4, 2021 –

PR Newswire

BERWYN, Pa., Jan. 14, 2021 /PRNewswire/ — AMETEK, Inc. (NYSE: AME) will issue its fourth quarter 2020 earnings release before the market opens on Thursday, February 4, 2021.

AMETEK will webcast its fourth quarter 2020 investor conference call on Thursday, February 4, 2021, beginning at 8:30 AM ET. The live audio webcast can be accessed by clicking on the Events & Presentations link in the “Investors” section of www.ametek.com. A replay of the call will also be archived on the website and will be available until the next quarterly earnings call. 

Corporate Profile:
AMETEK is a leading global manufacturer of electronic instruments and electromechanical devices with 2019 sales of approximately $5.0 billion. The AMETEK Growth Model integrates the Four Growth Strategies – Operational Excellence, New Product Development, Global and Market Expansion, and Strategic Acquisitions – with a disciplined focus on cash generation and capital deployment. AMETEK’s objective is double-digit percentage growth in earnings per share over the business cycle and a superior return on total capital. The common stock of AMETEK is a component of the S&P 500.

Contact:
AMETEK, Inc.
Kevin Coleman
Vice President, Investor Relations
1100 Cassatt Road
Berwyn, Pennsylvania 19312
[email protected] 
Phone: 610.889.5247

Cision View original content:http://www.prnewswire.com/news-releases/ametek-announces-fourth-quarter-2020-earnings-call-and-webcasted-investor-conference-call-information-301208029.html

SOURCE AMETEK, Inc.

Lipocine Announces USPTO Declaration Of Interference Between Lipocine And Clarus Patent Applications

PR Newswire

SALT LAKE CITY, Jan. 14, 2021 /PRNewswire/ — Lipocine Inc. (NASDAQ: LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, today announced that the Patent Trial and Appeal Board (“PTAB”) of the United States Patent and Trademark Office (“USPTO”) declared Interference No. 106,128 between Lipocine, Inc. (“the Senior Party”) owned U.S. Patent Application and Clarus Therapeutics, Inc. (“the Junior Party”) owned U.S. Patent Application. In preparation for the Interference, the USPTO withdrew the Clarus Application from issue.

This follows the pattern of previous Interferences as shown below:

  • Interference No. 106,045 decided in Lipocine’s favor and resulted in the cancellation of Clarus patent 8,828,428.
  • Interference No. 106,120 decided in Lipocine’s favor and resulted in the cancellation of Clarus application 15/723,976.

“We are pleased with the actions and judgements ordered by the PTAB which validates the strength of Lipocine’s patent portfolio,” said Dr. Mahesh Patel, Chairman, President and CEO of Lipocine.

About Lipocine
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine’s clinical development pipeline includes: TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, has received tentative approval from the FDA for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism, in adult males. LPCN 1144, an oral prodrug of bioidentical testosterone, recently completed a proof-of-concept clinical study demonstrating the potential utility in the treatment of non-cirrhotic NASH. LPCN 1144 is currently being studied in a Phase 2 clinical study. TLANDO XR, a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing. In a phase 2 clinical evaluation when administered as once daily or twice daily TLANDO XR met the typical primary and secondary end points. LPCN 1148 is an oral prodrug of bioidentical testosterone targeted for the treatment of cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. For more information. For more information, please visit www.lipocine.com.   

Forward-Looking Statements

This release contains “forward-looking statements” that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and include statements that are not historical facts regarding Lipocine’s product candidates and related clinical trials, the timing of completion of clinical trials, the potential uses and benefits of our product candidates, our product development efforts, the timing of processes related to intellectual property, and the timing of ongoing litigation. Investors are cautioned that all such forward-looking statements involve risks and uncertainties, including, without limitation, the risks that the FDA will not approve any of our products, risks related to our products, expected product benefits not being realized, clinical and regulatory expectations and plans not being realized, new regulatory developments and requirements, risks related to the FDA approval process including the receipt of regulatory approvals, the results and timing of clinical trials, patient acceptance of Lipocine’s products, the manufacturing and commercialization of Lipocine’s products, and other risks detailed in Lipocine’s filings with the SEC, including, without limitation, its Form 10-K and other reports on Forms 8-K and 10-Q, all of which can be obtained on the SEC website at www.sec.gov. Lipocine assumes no obligation to update or revise publicly any forward-looking statements contained in this release, except as required by law.

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/lipocine-announces-uspto-declaration-of-interference-between-lipocine-and-clarus-patent-applications-301208039.html

SOURCE Lipocine Inc.

Union Pacific Corporation Announces Fourth Quarter 2020 Earnings Release Date

PR Newswire

OMAHA, Neb., Jan. 14, 2021 /PRNewswire/ — Union Pacific Corporation (NYSE: UNP) will release fourth quarter 2020 financial and operating results on Thursday, January 21, 2021, at 8:00 a.m. ET. The company’s management team will host a conference call and live webcast at 8:45 a.m. ET.

Parties interested in participating via teleconference may dial 877-407-8293. International callers may dial 201-689-8349. A live webcast of the presentation and materials will be available in the investor relations section of Union Pacific’s website at www.up.com/investor. A replay of the audio webcast will be available shortly thereafter.

ABOUT UNION PACIFIC

Union Pacific (NYSE: UNP) delivers the goods families and businesses use every day with safe, reliable and efficient service. Operating in 23 western states, the company connects its customers and communities to the global economy. Trains are the most environmentally responsible way to move freight, helping Union Pacific protect future generations. More information about Union Pacific is available at www.up.com.  

www.up.com

www.facebook.com/unionpacific

www.twitter.com/unionpacific

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/union-pacific-corporation-announces-fourth-quarter-2020-earnings-release-date-301207486.html

SOURCE Union Pacific Corporation

Ipsidy Announces Agreement with Wipro to Combat Identity Fraud and Offer FIDO2 Compliant Passwordless Login for Customers Globally

LONG BEACH, NY, Jan. 14, 2021 (GLOBE NEWSWIRE) — Ipsidy Inc. (www.ipsidy.com) [OTCQB: IDTY], a leading provider of secure, mobile biometric identity solutions, including Identity as a Service (IDaaS), today announced an agreement with Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company,  to help enterprise customers combat identity fraud and to deliver seamless FIDO2 compliant Passwordless login tied to a proven identity.

Wipro helps its global customers across six continents thrive in a world defined by disruption and fueled by transformative technology. Under the agreement, Wipro will team with Ipsidy to offer innovative identity solutions to address the expanding demand for building trust and identity certainty in today’s online, digital world.

Verification of an individual’s identity during enrollment as well as ongoing authentication of that identity across the customer journey underpins the basis of a new form of trust and security. To that end, Wipro intends to offer Ipsidy’s facial biometric identity solutions, ProofTM and VerifiedTM , to provide enhanced identity assurance throughout the digital transformation journey.


Proof

TM by Ipsidy offers facial biometric identity verification utilizing trusted government-issued credentials and databases to help eliminate identity fraud during remote user and customer onboarding. Verified™ Essential, offered through Ipsidy’s partnership with LoginID, delivers a FIDO2 strong authentication and Passwordless access solution that securely and automatically creates a digital chain of trust between biometrically verified individuals, their accounts, and their devices. Instead of entering complex and often forgotten passwords, VerifiedTM  allows seamless biometric authentication of enterprise employees and customers to systems, web platforms, and mobile applications.

“Ipsidy is pleased to partner with Wipro to deliver our identity verification and FIDO2 authentication services across the globe” said Phillip Kumnick, CEO of Ipsidy. “Wipro is well-known for its market breadth and reputation for delivering innovative solutions to its customers as they grow their digital businesses.  We believe this agreement opens new opportunities for our business, as Wipro assists clients with the critical challenge of mitigating identity fraud and enhancing system security.”

For further information about these exciting solutions and how to join the Ipsidy Partner Network and resell our suite of mobile biometric solutions, contact Ipsidy at [email protected].

About Ipsidy



Ipsidy Inc.

 (OTCQB:IDTY) www.ipsidy.com, is Digital Identity. Ipsidy’s mission is to ensure our customers know the identity of their users with biometric certainty. Our Identity as a Service (IDaaS) platform delivers a suite of secure, mobile, facial biometric identity solutions, available to any vertical, anywhere. Our robust identity verification and authentication solutions work great on their own but even better together to help answer everyday questions: Who is applying for a loan? Who is sending money? Who is requesting an account change? Ipsidy is committed to providing seamless, accurate and speedy identity solutions that establish security and trust in today’s digital world.

Ipsidy is headquartered in New York and has operating subsidiaries: MultiPay in Colombia, www.multipay.com.co; Cards Plus in South Africa, www.cardsplus.co.za; Ipsidy Enterprises in the U.K. and Ipsidy Perú S.A.C. Further information on Ipsidy can be found at www.ipsidy.com or contact us at [email protected].

Contacts:

   
Ipsidy Inc.  
Phillip Kumnick, CEO
[email protected]


+1 (516) 274-8700

 

Notice Regarding Forward-Looking Statements

Information contained in this announcement may include “forward-looking statements.” All statements other than statements of historical facts included herein, including, without limitation, those regarding the financial position, business strategy, plans and objectives of management for future operations of both Ipsidy and its business partners, future service launches with customers, the outcome of pilots and new initiatives and customer pipeline are forward-looking statements. Such forward-looking statements are based on a number of assumptions regarding Ipsidy present and future business strategies, and the environment in which Ipsidy expects to operate in the future, which assumptions may or may not be fulfilled in practice. Implementation of some or all of the new services referred to is subject to regulatory or other third party approvals. Actual results may vary materially from the results anticipated by these forward-looking statements as a result of a variety of risk factors, including the risk that implementation, adoption and offering of the service by customers, consumers and others may take longer than anticipated, or may not occur at all; changes in laws, regulations and practices; changes in domestic and international economic and political conditions, the as yet uncertain impact of the Covid-19 pandemic and others. Additional risks may arise with respect to commencing operations in new countries and regions, of which Ipsidy is not fully aware at this time. See the Company’s Annual Report Form 10-K for the Fiscal Year ended December 31, 2019 filed at www.sec.gov for other risk factors which investors should consider. These forward-looking statements speak only as to the date of this announcement and cannot be relied upon as a guide to future performance. Ipsidy expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statements contained in this announcement to reflect any changes in its expectations with regard thereto or any change in events, conditions or circumstances on which any statement is based.



FuelCell Energy Announces Fourth Quarter and Full Year Fiscal 2020 Financial Results Conference Call on January 21, 2021 at 10 A.M. Eastern Time

DANBURY, Conn., Jan. 14, 2021 (GLOBE NEWSWIRE) — FuelCell Energy (Nasdaq: FCEL)  — a global leader in fuel cell technology — with a purpose of utilizing its proprietary, state-of-the-art fuel cell platforms to enable a world empowered by clean energy — today announced the upcoming release of its fourth quarter financial results prior to the Stock Market Open on Thursday, January 21, 2021.  FuelCell Energy management will host a conference call with investors beginning at 10:00 a.m. Eastern Time on Thursday, January 21, 2021 to discuss the fourth quarter and full year fiscal 2020 results.

Participants can access the live call via webcast on the Company website or by telephone as follows:

  • The live webcast of this call and supporting slide presentation will be available at www.fuelcellenergy.com.  To listen to the call, select ‘Investors’ on the home page, proceed to the ‘Events & presentations’ page and then click on the ‘Webcast’ link listed under the January 21st earnings call event listed, or click here
  • Alternatively, participants can dial 647-689-4106 and state FuelCell Energy or the conference ID number 9572604

The replay of the conference call will be available via webcast on the Company’s Investors page at www.fuelcellenergy.com approximately two hours after the conclusion of the call.


About FuelCell Energy

FuelCell Energy, Inc. (NASDAQ: FCEL) is a global leader in sustainable clean energy technologies that address some of the world’s most critical challenges around energy, safety and global urbanization. As a leading global manufacturer of proprietary fuel cell technology platforms, FuelCell Energy is uniquely positioned to serve customers worldwide with sustainable products and solutions for businesses, utilities, governments and municipalities. Our solutions are designed to enable a world empowered by clean energy, enhancing the quality of life for people around the globe. We target large-scale power users with our megawatt-class installations globally, and currently offer sub-megawatt solutions for smaller power consumers in Europe. To provide a frame of reference, one megawatt is adequate to continually power approximately 1,000 average sized U.S. homes. We develop turn-key distributed power generation solutions and operate and provide comprehensive service for the life of the power plant. Our fuel cell solution is a clean, efficient alternative to traditional combustion-based power generation, and is complementary to an energy mix consisting of intermittent sources of energy, such as solar and wind turbines. Our customer base includes utility companies, municipalities, universities, hospitals, government entities/military bases and a variety of industrial and commercial enterprises. Our leading geographic markets are currently the United States and South Korea, and we are pursuing opportunities in other countries around the world. FuelCell Energy, based in Connecticut, was founded in 1969.

SureSource, SureSource 1500, SureSource 3000, SureSource 4000, SureSource Recovery, SureSource Capture, SureSource Hydrogen, SureSource Storage, SureSource Service, SureSource Capital, FuelCell Energy, and FuelCell Energy logo are all trademarks of FuelCell Energy, Inc.

Visit us online at www.fuelcellenergy.com and follow us on Twitter @FuelCell_Energy.

SureSource, SureSource 1500, SureSource 3000, SureSource 4000, SureSource Recovery, SureSource Capture, SureSource Hydrogen, SureSource Storage, SureSource Service, SureSource Capital, FuelCell Energy, and FuelCell Energy logo are all trademarks of FuelCell Energy, Inc.

Contact:

FuelCell Energy
203.205.2491
[email protected]

Source: FuelCell Energy



Xalles Announces New Executive Team Members

WASHINGTON, DC, Jan. 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, announces that it has added key members to the senior management team.

Xalles Holdings has appointed Karen Nguyen as its Chief Marketing Officer. As CMO, Ms. Nguyen will lead the corporate marketing strategy for Xalles Holdings and will support each operating subsidiary through marketing tools, systems, and standards. Using her 15 years of experience in key corporate marketing roles and consulting business, Ms. Nguyen will drive a focused agenda across the Xalles Holdings portfolio.

A growth-focused leader, Ms. Nguyen brings a multi-faceted career as a marketeer and successful entrepreneur. Prior to her consulting practice advising clients across high-technology, finance, government, and retail, Ms. Nguyen was head of Worldwide Partner Marketing for Western Digital. In this dual role, she was instrumental in launching channel marketing programs across 90 countries and managed teams in the Americas, Europe and Asia. Prior to Western Digital, Ms. Nguyen was part of the Global Strategic Alliances team at Experian Marketing Services that identified fintech acquisitions and performed due diligence. She received her Bachelors and MBA from University of California, Irvine.

Everett Doolittle has been appointed as the President of Xalles Limited, a wholly owned subsidiary of Xalles Holdings Inc. As President, Mr. Doolittle will apply his 25 years of fintech business development experience in his new role, responsible for leveraging the technology and intellectual property of the X2X system for financial transaction reconciliation to grow the licensing and payment auditing business.

Mr. Doolittle led the business development of a technology based, financial supply chain management and eCommerce payment system called “PowerTrack” for U.S. Bank which evolved to a multi-bank payment network in a joint venture with Visa called “Syncada”. He also launched the “Financial Services Offshore Practice” supporting finance related corporate back office functions for UnitedHealth Group, UnitedHealthcare and Optum. Both international initiatives re-engineered operations, systems and workflow, including the process of invoice processing, audit and payment.

“Karen has a wealth of experience in creating brand identity across various market dynamics. She is not only innovative but has a track record of executing marketing strategies that drive financial value to organizations. Her expertise and vision will help propel Xalles forward during our next phase of growth,” stated Thomas Nash, Chief Executive Officer of Xalles Holdings. He added, “Having worked directly with Everett during the PowerTrack rollout across the Department of Defense, I am excited to see the results he will bring to Xalles and our financial transaction and payment auditing business lines.”

Ms. Nguyen and Mr. Doolittle will be instrumental in helping Xalles succeed as a fintech holding company, specializing in payment solutions and accretive fintech rollups.

In 2020, Xalles announced that it would proceed with accounting and auditing work to enable the company to uplist to OTCQB (Quotation Board) as well as offer shares through a Reg A+ public offering. The accounting and auditing tasks are now planned to be completed as soon as possible. Additional updates will be forthcoming on these activities and other previously announced transactions.

About Xalles Holdings Inc. (OTC: XALL)

Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: http://Xalles.com

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com

Investor Relations Contact:

[email protected]

www.Xalles.com

202.595.1299 Office



aTyr Pharma Announces Partner Kyorin Pharmaceutical, Co., Ltd. Completes Subject Visits for Phase 1 Trial of ATYR1923 in Japan

SAN DIEGO, Jan. 14, 2021 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that its partner Kyorin Pharmaceutical Co., Ltd., or Kyorin, a wholly owned subsidiary of Kyorin Holdings, Inc., has completed the last subject visit in its Phase 1 clinical trial of aTyr’s lead therapeutic candidate ATYR1923 (known as KRP-R120 in Japan). This achievement has triggered a milestone payment to aTyr.

“We applaud Kyorin for its timely advancement of this study. We are highly encouraged by their progress with the clinical program for ATYR1923 in Japan since becoming our partner early last year,” said Dr. Sanjay Shukla, M.D., M.S., President and Chief Executive Officer of aTyr.

The Phase 1 trial, which is being conducted by Kyorin, is a placebo-controlled study to evaluate the safety, pharmacokinetics and immunogenicity of ATYR1923 in 32 healthy Japanese male volunteers. Results from this study are intended to enable Kyorin to initiate patient trials in interstitial lung disease (ILD) in Japan.

Kyorin is aTyr’s partner for the development and commercialization of ATYR1923 for ILDs in Japan.

Abo
ut ATYR1923

aTyr is developing ATYR1923 as a potential therapeutic for patients with inflammatory lung diseases. ATYR1923, a fusion protein comprised of the immuno-modulatory domain of histidyl tRNA synthetase fused to the FC region of a human antibody, is a selective modulator of neuropilin-2 that downregulates the innate and adaptive immune response in inflammatory disease states. aTyr recently completed enrollment in a proof-of-concept Phase 1b/2a trial evaluating ATYR1923 in patients with pulmonary sarcoidosis, a form of interstitial lung disease. This Phase 1b/2a study is a multi-ascending dose, placebo-controlled, first-in-patient study of ATYR1923 that has been designed to evaluate the safety, tolerability, steroid sparing effect, immunogenicity and pharmacokinetics profile of multiple doses of ATYR1923. In response to the COVID-19 pandemic, aTyr completed a Phase 2 clinical trial with ATYR1923 in COVID-19 patients with severe respiratory complications. This Phase 2 study was a randomized, double blind, placebo-controlled study that was designed to evaluate the safety and preliminary efficacy of a single dose of ATYR1923.

Abo
ut aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

About Kyorin

Trusted among patients and professionals in the medical industry, Kyorin Pharmaceutical Co., Ltd. strives to be a company that contributes to public health and is recognized as one with social significance by improving its presence in specific therapeutic areas and through global discovery of novel drugs. Kyorin Pharmaceutical Co., Ltd. uses a franchise customer strategy where its marketing efforts are focused on respiratory, otolaryngology and urology. In drug discovery, it is deploying ‘selection and concentration’ and promoting activities aimed at first-in-class drug discovery, such as actively searching for and introducing external drug discovery themes as well as multi-tiered program development. For more information, please visit http://www.kyorin-pharm.co.jp.        

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements include statements regarding the potential therapeutic benefits and applications of ATYR1923; timelines and plans with respect to certain development activities (such as the scope and timelines of clinical trials), potential benefits of collaborations and certain development goals. These forward-looking statements also reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects, as reflected in or suggested by these forward-looking statements, are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. All forward-looking statements are based on estimates and assumptions by our management that, although we believe to be reasonable, are inherently uncertain. Furthermore, actual results may differ materially from those described in these forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, uncertainty regarding the COVID-19 pandemic, risks associated with the discovery, development and regulation of our product candidates, the risk that we or our partners may cease or delay preclinical or clinical development activities for any of our existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), the possibility that existing collaborations could be terminated early, and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those risks set forth in our most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and in our other SEC filings. Except as required by law, we assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

Contact:  
Ashlee Dunston  
Director, Investor Relations and Corporate Communications               

[email protected]
 



Sysco Announces New 2025 Seafood Sustainability Commitments

Continues Industry-Leading Alliance With World Wildlife Fund to Elevate Standards, Build Consumer Trust

HOUSTON, Jan. 14, 2021 (GLOBE NEWSWIRE) — Sysco Corporation (NYSE: SYY) today announced an expanded commitment to improve the sustainability of its seafood procurement practices and standards in collaboration with World Wildlife Fund (WWF). These new commitments build on past successes and continue to advance Sysco’s position as a global leader in seafood sustainability, set high standards for the seafood industry, establish long-term sustainability goals, and build consumer trust.

Through its continued collaboration with WWF, Sysco will expand the current responsible sourcing program for its U.S. broadline business to also include sourcing for its specialty and Canadian broadline business, as well as increase the purchase of certified responsible seafood. It also adds new commitments to prohibit the sale of endangered species, advance its traceability work and help address deforestation. Specifically, Sysco’s commitments include achieving by the end of 2025:


Improving Sourcing

  • Sourcing 100% of its top 15 (by volume) wild-caught Sysco Portico Brand seafood species groups from fisheries that are certified by the Marine Stewardship Council (MSC), in MSC full assessment, or in a comprehensive Fishery Improvement Project (FIP), and source at least 85% of this top 15 volume from fisheries that are MSC certified
  • Sourcing 100% of Sysco Portico Brand canned or pouched tuna products from fisheries that are MSC certified, in MSC full assessment, in a comprehensive FIP, or from companies that are members of the International Seafood Sustainability Association, and source at least 25% of this volume from fisheries that are MSC certified
  • Sourcing 100% of its top five (by volume) aquaculture Sysco Portico Brand seafood species groups from farms that are certified by the Aquaculture Stewardship Council (ASC), in ASC full assessment, in a credible Aquaculture Improvement Project , or at a minimum Best Aquaculture Practices 2-star certified, and source at least 20% of this top five volume from farms that are ASC certified


Advancing Traceability

  • Engaging with suppliers of Sysco Portico Brand farmed shrimp products to ensure supply chains are traceable to the farm’s geographic location and address issues of deforestation or conversion of natural ecosystems (i.e. mangrove ecosystems and other natural wetlands)
  • Working with WWF to adopt key traceability principles and build on the work of the Global Dialogue on Seafood Traceability


Protecting Endangered Species

  • Prohibiting the sale of endangered species for Sysco seafood products globally, already an immaterial portion of Sysco’s seafood sales

“As the world’s leading foodservice distributor, Sysco strives to deliver superior products and services to our customers in a way that balances the needs of people, products and planet,” said Neil Russell, Sysco’s senior vice president of corporate affairs and chief communications officer. “Together with WWF, we will continue working to implement sustainable sourcing practices that advance the health of fisheries and fishing communities around the world.”

Sysco has held a successful partnership on seafood sustainability with WWF since 2009. The company’s commitments during this time have resulted in its sourcing over 700 million pounds of more sustainable seafood, securing the livelihoods for more than 100,000 people, and improving protections for species and habitats worldwide.

“Sysco has been a leader in its industry and the global movement to ensure more sustainable seafood production worldwide,” said Caroline Tippett, senior director of seafood markets at WWF. “Due to its direct engagement, Sysco has influenced global supply chains, markets and fisheries to engage in the journey towards producing more responsible seafood. We greatly commend Sysco’s continued commitment to this movement with its new, even more robust 2025 commitment goals. These efforts help safeguard the natural environment, the livelihoods of people who depend on these resources, and support the future stability of the seafood industry as a whole.”

To learn more about Sysco’s commitment to sustainable seafood, read the Sysco and WWF Seafood Sustainability Report.


About Sysco


Sysco is the global leader in selling, marketing and distributing food products to restaurants, healthcare and educational facilities, lodging establishments and other customers who prepare meals away from home. Its family of products also includes equipment and supplies for the foodservice and hospitality industries. With more than 57,000 associates, the company operates 326 distribution facilities worldwide and serves more than 625,000 customer locations. For fiscal 2020 that ended June 27, 2020, the company generated sales of more than $52 billion. Information about our CSR program, including Sysco’s 2020 Corporate Social Responsibility Report, can be found at www.sysco.com/csr2020report.

For more information, visit www.sysco.com or connect with Sysco on Facebook at www.facebook.com/SyscoCorporation or Twitter at https://twitter.com/Sysco. For important news and information regarding Sysco, visit the Investor Relations section of the company’s Internet home page at investors.sysco.com, which Sysco plans to use as a primary channel for publishing key information to its investors, some of which may contain material and previously non-public information. In addition, investors should continue to review our news releases and filings with the SEC. It is possible that the information we disclose through any of these channels of distribution could be deemed to be material information. 

For more information contact:       

Shannon Mutschler                                            
Media Contact                                                                                                              
[email protected]
T 281-584-4059                                                

 



ATM Subsidiary, Sonoran Flower CBD Company, Acquirers Omni Potent Meds, an Arizona Craft Cannabis Grower

TUCSON, AZ, Jan. 14, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Anything Technologies Media, Inc. (OTC: EXMT), announced today that it’s subsidiary, Sonoran Flower has acquired Omni Potent Meds, A Craft Cannabis grower. This acquisition expects to set Sonoran Flower apart in the Arizona Cannabis industry offering a quality product when adult use becomes legal on January 19th. Sonoran Flower looks to sell Omni Potent Meds products wholesale to all dispensaries across the state as a Craft Brand catering to the connoisseur. Omni’s Product line consists of flower, gel caps, edibles, vapes and wax.

“This is a huge benefit to the company as the Omni Potent Meds Brand has an established customer base in Arizona which will help as we look to expand into the Cannabis market by growing and distributing Cannabis to dispensaries in Arizona,” stated Lee Katterman, CEO of ATM.

The passing of Cannabis for recreational use in Arizona with the passage of Arizona’s Proposition 207 – the measure that legalizes recreational use of cannabis throughout the state. This passage of 207 along with the House voting to Decriminalize the use of Cannabis, goes hand in hand with President-elect’s promise to decriminalize cannabis on a federal level. ATM will actively update its shareholders on its progress in this business space.

About Sonoran Flower LLC.

https://sonoranflower.com/store

Sonoran Flower was built on the belief that nature holds everything we need to heal. We are a multifaceted organization that cultivates, processes, and sells wholesale and retail hemp goods. We procure and produce top-quality hemp seeds, smokable hemp flower, hemp biomass, distillates, isolates and products such as vape, lotions, salves, and Hemp Beverage.

To Buy Sonoran Flower CBD Products go to: https://sonoranflower.com/store or call 520-303-HEMP (4367)

Please follow Sonoran Flower on Instagram @ https://www.instagram.com/azgrowbros/

Follow us on Twitter @
https://twitter.com/anythingtechmed

Follow us on Instagram @
https://www.instagram.com/anythingcbdmeds/

and Facebook @ https://www.facebook.com/AnythingTechMed/

About Amethyst Beverage:
https://www.amethystbeverage.com/

Amethyst Beverage, a Reno, NV based business, was established in October 2016 mostly as a directive to support a Philanthropy effort toward Cancer associated with Children and Adults. A portion of all sales will be contributed to several organizations nationally.

Currently, Amethyst Beverage is the only water in the marketplace to carry Patented, USDA Organic, Vegan and Kosher certifications, and is also the only flavored (Strawberry/Watermelon, Orange/Mango, Pineapple/Coconut, Cran/Razz, Cucumber/Mint and Peach) alkaline water with fulvic acid containing 70 ionic minerals as well.

About Anything Technologies Media, Inc.

Anything Technologies Media is a manufacturing and marketing company involved in the sales and marketing of CBD Health products and software applications. ATM is the parent company of subsidiary Corporations and is focused on partnerships and acquisitions in new technologies and manufacturing sectors. The company and partners each have their own professional management team with extensive backgrounds in finance, manufacturing, marketing and distribution. ATM’s goal is to combine the expertise of our team members to create a cohesive force, which will carry the company forward in the marketplace.


https://anythingtechnologiesmedia.com/tech-market/

NinjaQuestion on Instagram @
https://www.instagram.com/ninjaquestion/

Safe Harbor Statement

Certain statements made in this press release constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “Looks to” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company does not undertake any obligation to update or publicly release any revisions to forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

Contact:
Anything Technologies Media, Inc.
[email protected]



GridGain 8.8 Advances Its Multi-Tier Database Engine to Scale Beyond Available Memory Capacity and Meet Growing Customer Demand

Improved storage utilization reduces total cost of ownership; expanded memory quota for SQL enables complex real-time analytics; enhanced security allows data encryption at rest

FOSTER CITY, Calif., Jan. 14, 2021 (GLOBE NEWSWIRE) — GridGain® Systems, provider of enterprise-grade in-memory computing solutions powered by the Apache® Ignite® distributed database, today announced GridGain 8.8, the latest release of the company’s in-memory computing platform. The release features enhanced support for GridGain’s multi-tier database engine, which scales up and out across memory and disk. The changes enable customers to leverage the disk tier of the database to query much larger datasets, reduce total cost of ownership, and secure sensitive or personal data at rest. Companies can now use GridGain for a greater number of production use cases, ranging from complex real-time analytics to mission-critical transactional workloads.

“As our customers expand their use of GridGain, they increasingly require the flexibility to scale workloads beyond available memory capacity,” said Abe Kleinfeld, president and CEO of GridGain. “As a result, we are continuing to evolve our data persistence technology to simplify GridGain cluster management, reduce disk requirements and improve performance, while lowering TCO and accelerating time to value. The combination of more effective disk utilization and higher memory quotas for SQL allows GridGain to support significantly larger and more complex real-time analytics use cases.”

GridGain’s multi-tier database engine enables companies to build modern applications that support transactional and analytical workloads on the same dataset by using Apache Ignite as a database that scales beyond the available memory capacity. Ignite allocates memory for hot data and accesses the disk tier whenever applications query cold records.

Key features of GridGain 8.8

  • Data compression – Reduces memory and disk space requirements for storing data. The dictionary-based cache entry compression is built on the Zstandard library, and a pre-trained dictionary can allow compression ratios of up to 60% on real-world scenarios. If the load pattern is I/O bound, then enabling native persistence can save space while also improving performance. Available in GridGain Ultimate Edition.
  • Advanced seamless disk space defragmentation – Improves GridGain’s persistence management. Defragmentation shrinks data files and reclaims disk space while still storing the current cached data durably on a disk. Available in all GridGain editions.
  • SQL memory quotas on node or query level – Prevents out-of-memory issues when executing SQL queries requiring significant memory space. Support for offloading data to the disk tier enables greedy or complex analytical queries to pull and process gigabytes of data while executing and returning the result back to an application. Available in all GridGain editions.
  • Transparent data encryption – Improves security of data stored in the cluster by encrypting data at rest. New procedures for managing Cache and Mater encryption keys support data encryption in production environments. Available in all GridGain editions.

GridGain will be hosting a webinar, “New Advances in GridGain’s Multi-Tier Database Engine,” on February 3, 2021 at 10:00 PST / 1:00 EST.

Availability

GridGain 8.8 is available now at https://www.gridgain.com/resources/download.

Additional Resources

To learn more about the GridGain in-memory computing platform:

About GridGain Systems

GridGain Systems is revolutionizing real-time data access and processing by offering an in-memory computing platform built on Apache® Ignite®. Common use cases for the GridGain platform include application acceleration and as a digital integration hub for real-time data access across data sources and applications. GridGain solutions are used by global enterprises in financial services, software, e-commerce, retail, online business services, healthcare, telecom, transportation and other major sectors, with a client list that includes ING, Raymond James, American Express, Finastra, UPS, Hewlett Packard Enterprise, Microsoft, American Airlines, Agilent, and UnitedHealthcare.

GridGain delivers unprecedented speed, massive scalability and real-time data access for both legacy and greenfield applications. Deployed on a distributed cluster of commodity servers, GridGain software can reside between the application and data layers (RDBMS, NoSQL and Apache® Hadoop®), requiring no rip-and-replace of the existing databases, or it can be deployed as an in-memory database. For more information, visit gridgain.com.

CONTACT:

Brigit Valencia
For GridGain Systems
[email protected]
(360) 597-4516

GridGain is a trademark or registered trademark of GridGain Systems, Inc. Apache, Apache Ignite, and Ignite are trademarks of The Apache Software Foundation. All other product and company names herein may be trademarks of their registered owners.